Last edition
News about "IMAAVY"
US FDA Approves IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia
The US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia, based on durable hemoglobin responses in phase 2/3.
IMAAVY | 26/08/2026 | By News Bureau
Johnson & Johnson Secures FDA Priority Review for Imaavy in Rare Blood Disorder
Johnson & Johnson moves closer to delivering a first-in-class treatment for Warm Autoimmune Haemolytic Anaemia with FDA Priority Review for Imaavy.
Imaavy | 28/04/2026 | By News Bureau | 132
Johnson & Johnson Submits sBLA to US FDA for IMAAVY in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson has filed a supplemental biologics application seeking US approval of IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia, a rare disorder with no currently approved treatments.
IMAAVY | 26/02/2026 | By News Bureau | 293
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy